dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Muu lepingAvalik

Leping

Sotsiaalministeerium · 11. detsember 2018
Viit
1.8-2/772-1
Registreeritud
11. detsember 2018
Dokumendi liik
Muu leping
Funktsioon
1.8 Finantsplaneerimine ja raamatupidamisarvestus
Sari
1.8-2 Lepingud (töövõtt ja käsundus juriidiliste isikutega, koostöölepe kulude hüvitamiseks, haldus, liising, üür-rent, kindlustus, müük, litsentsid, ost, varaline vastutus, varakasutus, andmevahetus) koos aktidega
Toimik
1.8-2/2024
Vastutaja
Mari Teesalu (Sotsiaalministeerium, Kantsleri vastutusvaldkond, e-teenuste asekantsleri vastutusvaldkond, Analüüsi ja statistika osakond)

Failid

  • 📎1.1-5772-1 11.12.2018 Muu leping.bdoc507 KB

Sisu (failidest)

EJP RD JTC 2019: MoU European Joint Programme on Rare Diseases (EJP RD) Call for Proposals 2019 "Transnational research projects to accelerate diagnosis and/or explore disease progression and mechanisms of rare diseases” Memorandum of Understanding (MoU) on International Cooperation in Research Funding within the Framework of the EJP on Rare Diseases JTC 2019 Established between the following Parties  Austrian Science Fund (FWF), Austria  Research Foundation Flanders (FWO), Belgium, Flanders  Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium, Wallonia  Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada  Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)  Ministry of Education, Youth and Sports (MEYS), Czech Republic  Ministry of Social Affairs of Estonia (MoSAE), Estonia  Academy of Finland (AKA), Finland  French National Research Agency (ANR), France  French Foundation for Rare Diseases (FFRD), France  Federal Ministry of Education and Research (BMBF), Germany  German Research Foundation (DFG), Germany  General Secretariat for Research and Technology (GSRT), Greece  National Research, Development and Innovation Office (NKFIH), Hungary  Health Research Board, (HRB), Ireland  Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel  Italian Ministry of Health (MoH-IT), Italy  Ministry of Education, Universities and Research (MIUR), Italy  Regional Foundation for Biomedical Research (FRRB), Lombardy (Italy)  Tuscany Region (RT/TuscReg), Tuscany (Italy)  Research Council of Lithuania (RCL), Lithuania  National Research Fund (FNR), Luxembourg  National Centre for Research and Development (NCBR), Poland  The Foundation for Science and Technology (FCT), Portugal  Slovak Academy of Sciences (SAS), Slovakia  National Institute of Health Carlos III (ISCIII), Spain  Swedish Research Council (SRC), Sweden  Vinnova, Sweden EJP RD JTC 2019: MoU  Swiss National Science Foundation (SNSF), Switzerland  Netherlands Organization for Health Research and Development (ZonMw), The Netherlands  The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey  The French National Institute of Health and Medical Research (INSERM), France (will provide dedicated funding only to Patient Advocacy Organisations) EJP RD JTC 2019: MoU PREAMBLE There are at least 7000 distinct rare diseases, the great majority being of genetic origin. Although individually rare, taken together rare diseases affect at least 26-30 million people in Europe. Moreover, they represent a major issue in health care: a large number of these diseases have an early or very early onset and/or lead to a significant decrease of life expectancy. Moreover, most of them cause chronic illnesses with a large impact on quality of life and the health care system. Therefore, research on rare diseases is needed to provide knowledge for prevention, diagnosis and better care of patients. Yet, research is hampered by lack of resources at several levels: (1) Few scientists work on any given specific disease, (2) There are few patients per disease and they are scattered over large geographic areas, causing difficulties to assemble the necessary cohorts, (3) Existing databases and bio-material collections are usually local, small, and not accessible or standardised, (4) The complex clinical phenotypes of these diseases require interdisciplinary cooperation to improve research and treatment. In this context, the ERA-Net E-Rare has successfully implemented ten Joint Transnational Calls for rare disease research projects since 2006. This effort is now continued in the frame of the European Joint Programme on Rare Diseases (EJP RD) that has been established to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC). Under the umbrella of the EJP RD the above listed Parties decided to open the joint call for funding multilateral research projects on rare diseases (JTC 2019). This Memorandum of Understanding (MoU) is a mutual statement of intention among the Parties. It serves to document the commitment of the Parties who agree to make every reasonable effort to fulfil the intents expressed in this joint call as well as the intended financial framework. The aim of this Memorandum of Understanding (MoU) is to establish the principles and procedures to be adopted by all Parties in the Joint Transnational Call JTC 2019:  Launching a common call for proposals  Receiving collaborative proposals  Setting up a common evaluation and selection procedure  Providing funding for the proposals selected according to the final ranking list For each Party, the MoU will come into force on the date of signature by the Party’s authorized representative and shall remain in force until the end of submission of the final report of the funded projects. The MoU may be amended or modified by written agreement of all signatories or their authorized representatives. Details on the implementation of the joint call are outlined in the document “Governance of the call and evaluation procedure”. The Parties agree as follows. EJP RD JTC 2019: MoU 1. CONTENT OF THE CALL It is hereby agreed that the Parties shall launch a transnational programme "Transnational research projects to accelerate diagnosis and/or explore disease progression and mechanisms of rare diseases" which will be jointly managed and financed by the participating organisations that are members of the EJP RD, according to their respective legal framework and regulations. The programme will be implemented by a call for proposals to be launched and processed in 2019-2020. The call will be opened simultaneously by the Parties in their respective countries and regions. 2. GOVERNANCE OF THE CALL AND EVALUATION PROCEDURE The governance of the call, its organization and the evaluation procedures are detailed in the document “Governance of the call and evaluation procedure”. All decisions concerning the JTC 2019 call procedures and transnational project funding will be taken by the Call Steering Committee (CSC) together with the European Commission. The Joint Call Secretariat (JCS) of JTC 2019 will be organized by DLR-PT, Germany. The responsibilities of the CSC and the JCS are detailed in the document “Governance of the call and evaluation procedure”. The scientific assessment of applications will be undertaken by a Scientific Evaluation Committee (SEC) on the basis of scientific quality and evaluation criteria as specified in the document “Governance of the call and evaluation procedure”. The CSC will select proposals for funding according to the reviews and the final ranking list established by the SEC. Subsequently the final decision will be made by the respective national/regional funding organisations. A two-stage submission/evaluation procedure for joint proposals with a rebuttal stage shall be applied. 3. ELIGIBILITY OF APPLICATIONS The eligibility of institutions, researchers, patient organisations and costs, as well as complementary administrative requirements are subject to the country/regional Party’s regulations and legal framework and may therefore vary from one Party to another. Information needs to be provided in time and form according to relevant Party’s regulations for research funding. The general eligibility rules for this call are specified in the call text and the national/regional criteria in the guidelines document. 4. FUNDING BUDGETS AND PROCEDURES The intended contribution by each participating organisation is listed below. Envisioned amount of Country/Region Participating organisation funding (M€ for 3 years) Austria FWF 0.6 EJP RD JTC 2019: MoU Belgium/Flanders FWO 0.7 Belgium/French speaking F.R.S.-FNRS 0.24 community Canada CIHR-IG 1 1.0 Canada FRQS 0.33 Czech Republic MEYS 0.6 Estonia MoSAE 0.075 Finland AKA 0.6 France ANR 3.0 France FFRD 0.1 Germany BMBF 3.0 Germany DFG 3.0 Greece GSRT 1.0 Hungary NKFIH 0.2 Israel CSO/MOH 0.3 Ireland HRB 0.37 Italy MoH-IT 2.0 Italy MIUR 0.4 Italy FRRB 1.3 Italy RT/TuscReg 0.3 Lithuania RCL 0.1 Luxembourg FNR 0.3 Poland NCBR 0.6 Portugal FCT 0.3 Slovakia SAS 0.12 Spain ISCIII 0.5 1 CIHR-IG will fund to a maximum of $1.5 million Canadian over three years (currently equivalent to 1 Mio €) to support operational research costs only. The Canadian amount will not be adjusted to reflect conversion rate changes. EJP RD JTC 2019: MoU Switzerland SNSF2 0.84 Sweden SRC 1.5 Sweden Vinnova 1.0 The Netherlands ZonMw3 1.8 Turkey TUBITAK 1.0 Multinational, funding for PAO INSERM 0.5 The funds provided by the Parties to this MoU (table above) will be used for research projects carried out by research partners and institutions according to their respective countries’ regulations and legal framework and based on the scientific quality of the proposals reflected by the SEC evaluation decision. As far as possible, the proposals will be funded in accordance with the ranking order as a result of the SEC advice, starting with the top-scoring proposals. In order to avoid early funding gaps, each funding organization participating in the joint call is asked to match as accurately and realistically as possible the financial demand from the proposals with the budget earmarked for the call. The final decision on funding will be taken by the respective national/regional funding organizations involved in the application. The respective national/regional funding organization will decide upon the information provided by the CSC after recommendations from the SEC. Selected projects will receive funding directly from the corresponding national/regional funding organizations according to their respective policies and guidelines. Funding will be awarded and administered according to the terms and conditions of responsible national/regional funding organizations taking into account all other applicable national/regional regulations and legal framework. 5. REPORTING The coordinators of all funded projects must submit brief annual scientific project reports and a final scientific project report in the form of an online questionnaire. This monitoring will be under the responsibility of CSH-MOH, Israel, and FNRS, Belgium, which is responsible for the online monitoring system for the funded projects In addition, each team may have to report to its funding organisation, in accordance with the respective national/regional funding organisations’ regulations. 6. MISCELLANEOUS The MoU shall become effective by the signatures of the Parties on the date given below. It shall cover the entire funding period of the joint call research projects at least until all 2 SNSF has earmarked a budget of 1.0 million Swiss Francs over three years (currently equivalent to 0.84 Mio €). 3 Maximum funding of 250,000 € for Dutch participation per project EJP RD JTC 2019: MoU agreements are settled (expected to start early in 2020 and to last at least 3 years), except force majeure, and including any extension period to be specified later. This MoU represents the intentions of the Parties, made in good faith, to collaborate in respect of the joint transnational call for research projects on rare diseases. Each Party hereto understands and agrees that nothing contained in this MoU is intended to constitute a legally binding obligation. The undersigned funding organizations, participants of EJP RD, have agreed to issue a joint call at the end of 2018, in accordance with the documents developed for these activities, in each country/region, including:  Call text  Governance of the call and evaluation procedure  Guidelines for applicants  Pre-proposal application form  Full proposal application form 7. SIGNATURES EJP RD JTC 2019: MoU For Austrian Science Fund (FWF), Austria NAME: Prof. KLEMENT TOCKNER POSITION: President of FWF Signature: Date: EJP RD JTC 2019: MoU For Research Foundation - Flanders (FWO), Flanders, Belgium NAME: Dr. Hans Willems POSITION: Secretary General Signatures: Date: EJP RD JTC 2019: MoU Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium NAME: Dr. ir. Véronique Halloin POSITION: Secretary General Signature: Date: EJP RD JTC 2019: MoU For Canadian Institutes of Health Research Institute of Genetics (CIHR-IG) NAME: Dr. Michael Strong POSITION: Scientific Director, CIHR Institute of Genetics Signature: Date: EJP RD JTC 2019: MoU For Fonds de Recherche du Québec-Santé (FRQS), Québec (Canada) NAME: Dr. Serge Marchand POSITION: Scientific Director, Fonds de recherche du Québec-Santé (FRQS) Signature: Date: EJP RD JTC 2019: MoU For Ministry of Education, Youth and Sports (MEYS), Czech Republic NAME: PhDr. Pavel Doleček, Ph.D. POSITION: Deputy Minister, Research and Higher Education section Signature: Date: EJP RD JTC 2019: MoU For Ministry of Social Affairs of Estonia (MoSAE), Estonia NAME: Marika Priske POSITION: Secretary General Signature: Date: EJP RD JTC 2019: MoU For Academy of Finland (AKA), Finland NAME: Dr. Riitta Maijala POSITION: Vice President, research Signature: Date: EJP RD JTC 2019: MoU For French National Research Agency (ANR), France NAME: Thierry Damerval POSITION: Président Directeur Général Signature: Date: EJP RD JTC 2019: MoU For French Foundation for Rare Diseases (FFRD), France NAME: Daniel Scherman POSITION: Director Signature: Date: EJP RD JTC 2019: MoU For Federal Ministry of Education and Research (BMBF), Germany NAME: Dr. Renate Loskill POSITION: Head of department Signature: Date: EJP RD JTC 2019: MoU For German Research Foundation (DFG), Germany NAME: Dr. Annette Schmidtmann POSITION: Head of Department for Scientific Affairs Signature: Date: EJP RD JTC 2019: MoU For General Secretariat for Research and Technology (GSRT), Greece NAME: Dr. Patricia Kyprianidou POSITION: Secretary General for Research and Technology Signature: Date: EJP RD JTC 2019: MoU For National Research, Development and Innovation Office (NKFIH), Hungary NAME: Dr. József Pálinkás POSITION: President Signature: Date: EJP RD JTC 2019: MoU For Health Research Board, (HRB), Ireland NAME Dr. Mairead O’Driscoll POSITION: Director of research Strategy and Funding Signature: Date: EJP RD JTC 2019: MoU For the Chief Scientist Office, Ministry of Health (CSO-MOH), Israel NAME Prof. Avi Israeli POSITION: Chief Scientist of the Ministry of Health Signature: Date: EJP RD JTC 2019: MoU For Ministry of Health – Ministero della Salute (MOH-IT), Italy NAME: Dr. Giselda Scalera POSITION: Head Office 5 (Health Research IRCCS), Directorate General for Research and Innovation in Healthcare, Ministry of Health Signature: Date: EJP RD JTC 2019: MoU For Ministry of Education, Universities and Research (MIUR), Italy NAME: Dr. Vincenzo Di Felice POSITION: Director General Signature: Date: EJP RD JTC 2019: MoU For Regional Foundation for Biomedical Research (FRRB), Lombardy (Italy) NAME: Marina Gerini POSITION: General Director Signature: Date: EJP RD JTC 2019: MoU For Tuscany Region (RT/TuscReg), Tuscany (Italy) NAME: Katia Belvedere POSITION: Head of Office, Legal advice, administrative support to research and clinical governance bodies, Directorate for citizenship right and social cohesion, Tuscany Region Signature: Date: EJP RD JTC 2019: MoU For Research Council of Lithuania (RCL), Lithuania NAME: Valdemaras Razumas POSITION: Chairman of the Research Council of Lithuania Signature: Date: EJP RD JTC 2019: MoU For National Research Fund (FNR), Luxembourg NAME: Prof. Dr. Marc Schiltz POSITION: Secretary General Signature: Date: EJP RD JTC 2019: MoU For National Centre for Research and Development (NCBR), Poland NAME: Prof. Maciej Chorowski POSITION: Director Signature: Date: EJP RD JTC 2019: MoU For The Foundation for Science and Technology (FCT), Portugal NAME: Paulo Ferrão POSITION: President Signature: Date: EJP RD JTC 2019: MoU For Slovak Academy of Sciences (SAS), Slovakia NAME: Prof. Pavol ŠAJGALÍK POSITION: President Signature: Date: EJP RD JTC 2019: MoU For National Institute of Health Carlos III Instituto de Salud Carlos III (ISCIII)] Spain NAME: Dra. Raquel Yotti Álvarez POSITION: Director General Signature: Date: EJP RD JTC 2019: MoU For Swedish Research Council (SRC), Sweden NAME: Sven Stafström POSITION: Director General, The Swedish Research Council Signature: Date: EJP RD JTC 2019: MoU For Vinnova, Sweden NAME: Darja Isaksson POSITION: Director General for Vinnova Signature: Date: EJP RD JTC 2019: MoU For Swiss National Science Foundation (SNSF) NAME: Dr. Ayșim Yılmaz POSITION: Head, Division Biology and Medicine, Swiss National Science Foundation Signature: Date: EJP RD JTC 2019: MoU The Netherlands Organisation for Health Research and Development (ZonMw), The Netherlands NAME: Dr. Martijntje Bakker POSITION: Co-director ZonMw Signature: Date: EJP RD JTC 2019: MoU For The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey NAME: Prof. Dr. Hasan Mandal POSITION: President Signature: Date: EJP RD JTC 2019: MoU ANNEX: EJP RD JTC 2019 Call Steering Committee (CSC) composition  Austrian Science Fund (FWF), Austria Representative Name: Dr. Stephanie Resch Position: Scientific officer Proxy Name: Anita Stuertz, Dipl.-Ing. Position: Operational Project Officer  Research Foundation - Flanders (FWO), Flanders, Belgium Representative Name: Alain Deleener Position: Science Policy Advisor Strategic Research Programmes Proxy Name: Toon Monbaliu Position: Advisor Research Affairs  Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium Representative Name: Florence Quist Position: Scientific officer Proxy Name: Joël Groeneveld Position: Policy officer  Canadian Institutes of Health Research (CIHR-IG), Canada Representative Name: Maxime Beaudoin Position: Proxy Name: Marilyn Desrosiers Position: Deputy Director, Strategic Program Design and Analytics, CIHR  Fonds de Recherche du Québec-Santé (FRQS), Québec (Canada) EJP RD JTC 2019: MoU Representative Name: Sylvain Charbonneau Position: Director, Programs and Partnerships, FRQS Proxy Name: Maxime Beaudoin Position: Program Manager, FRQS  Ministry of Education, Youth and Sports (MEYS), Czech Republic Representative Name: Mgr. Daniel Hanšpach Position: Officer Proxy Name: Mgr. Monika Kocmanová Position: Head of Unit of the European Research Area  Ministry of Social Affairs of Estonia (MoSAE), Estonia Representative Name: Heli Paluste Position: Head of Health Care Unit Proxy Name: Angela Ivask Position: Scientific Adviser for Health Policy  Academy of Finland (AKA), Finland Representative Name: Heikki Vilen Position: Science adviser Proxy Name: Antti Hautaniemi Position: Science Adviser  French National Research Agency (ANR), France Representative Name: Dr. Daria Julkowska Position: Scientific Coordinator EJP RD JTC 2019: MoU Proxy Name: Dr. Florence Guillot Position: Scientific Officer  French Foundation for Rare Diseases (FFRD), France Representative Name: Daniel Scherman Position: Proxy Name: Ingrid Zwaenepool Position:  Federal Ministry of Education and Research (BMBF), Germany Representative Name: Dr. Ralph Schuster Position: Scientific officer Proxy Name: Dr. Katarzyna Saedler Position: Scientific officer Name: Dr. Michaela Fersch Position: Scientific officer  German Research Foundation (DFG), Germany Representative Name: Dr. Katja Grossmann Position: Programme Officer Proxy Name: Dr. Theodora Hogenkamp Position: Programme Director  General Secretariat for Research and Technology (GSRT), Greece Representative Name: Sofia Dimitropoulou Position: Programme Officer EJP RD JTC 2019: MoU  National Research, Development and Innovation Office (NKFIH), Hungary Representative Name: Dr. Gábor Tóth Position: Department of Research and Development Proxy Name: Dr. Előd Nemerkényi Position: Assistant of International Affairs  Health Research Board (HRB), Ireland Representative Name: Annalisa Montesanti PhD Position: Programme Manager  Chief Scientist Office, Ministry of Health (CSO-MOH), Israel Representative Name: Prof. Avi Israeli Position: Chief Scientist Proxy Name: Dr. Irit Allon Position:  Ministry of Health – Ministero della Salute (MOH), Italy Representative Name: Dr. Giselda Scalera Position: Head Office 5 (Health Research IRCCS) Proxy Name: Dr. Raffaele Ruocco Position:  Ministry of Education, Universities and Research (MIUR), Italy Representative Name: Aldo Covello Position: Proxy Name: Valeria Cardia EJP RD JTC 2019: MoU Position:  Regional Foundation for Biomedical Research (FRRB), Lombardy (Italy) Representative Name: Marina Gerini Position: General Director Proxy Name: Paola Bello Position: EU Funding officer  Tuscany Region (RT/TuscReg), Tuscany (Italy) Representative Name: Donatella Tanini Position: Proxy Name: Teresa Vieri Position:  Research Council of Lithuania (RCL), Lithuania Representative Name: Živilė Ružele Position Chief Officer Proxy Name: Jūratė Devižienė Position: Head of International Programmes Unit  National Research Fund (FNR), Luxembourg Representative Name: Sean Sapcariu Position: Programme Manager Proxy Name: Marie-Claude Marx Position: Programme Manager  National Centre for Research and Development (NCBR), Poland EJP RD JTC 2019: MoU Representative Name: Marcin Chmielewski Position: Programme officer   The Foundation for Science and Technology (FCT), Portugal Representative Name: Anabela Isidro Position: Science Officer Proxy Name: Rita Cavaleiro Position: Science Officer  Slovak Academy of Sciences (SAS), Slovakia Representative Name: Jan Barancik, PhD Position: Head, International Cooperation Dpt. Proxy Name: Zuzana Cernakova, PhD Position: Programme officer  National Institute of Health Carlos III (ISCIII), Spain Representative Name: Rafael de Andrés Medina Position: Head of the EU and Internationalization Division [EU+Int] Proxy Name: Ignacio Baanante Position: Scientific Officer  Swedish Research Council (SRC), Sweden Representative Name: Malin Eklund Position: Scientific officer  Vinnova, Sweden Representative Name: Frida Lundmark Position: Scientific officer EJP RD JTC 2019: MoU  Swiss National Science Foundation (SNSF), Switzerland Representative Name: Dr. Christoph Meier Position: Scientific officer  The Netherlands Organisation for Health Research and Development (ZonMw), The Netherlands Representative Name: Dr. Sonja van Weely Position: Programme officer Proxy Name: Dr. Ir. Harald Moonen Position: Programme Officer  The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey Representative Name: Dr. Jale Şahin Position: Programme officier
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel